Jefferies analyst Kaumil Gajrawala lowered the firm’s price target on Clorox (CLX) to $139 from $151 and keeps a Buy rating on the shares. Clorox faces a challenging second half amid geopolitical tensions, inflation, and ongoing share losses, with only limited category improvement, the analyst tells investors in a research note. Q3 organic growth is expected to slightly miss and FY26 EPS guidance may be lowered, with further estimate cuts and longer-term outlook commentary remaining the key focus, the firm adds.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLX:
- Ex-Dividend Date Nearing for These 10 Stocks – Week of April 20, 2026
- The Week That Was, The Week Ahead: Macro and Markets, April 19
- Midday Fly By: Netflix slumps as co-founder Hastings announces exit
- Apple upgraded, Qualcomm downgraded: Wall Street’s top analyst calls
- Clorox downgraded to Underweight from Neutral at JPMorgan
